Arquer Diagnostics
is a UK-based company committed to manufacturing
and marketing innovative, non-invasive
cancer tests for diagnosis and monitoring
VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is leading the way in non-invasive tests for diagnosing and monitoring cancer.
Our tests use patented technology to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
Our tests use patented technology to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
Our accurate and reliable tests meet the demands of patients, clinicians and payers for non-invasive, pain-free, healthcare technologies which not only improve patient care but reduce healthcare costs.
ADXBLADDER is the first of Arquer’s MCM5 tests to be released as a CE marked bladder cancer test and we are also currently testing the technology in prostate and endometrial cancers.
Latest News
Arquer Diagnostics @Arquer Diagnostics
It's #BladderCancerAwarenessMonth, so join us in raising awareness of this condition and strengthening the support on offer to those affected by bladder cancer. #ADXBLADDER has already played a vital role in the detection of #bladdercancer recurrence and we hope this continues. https://t.co/j4aXWCxrOt
Arquer Diagnostics @Arquer Diagnostics
Our #technology is based on the fact that MCM-positive cells aren't normally present in bodily fluids in the absence of #cancer. From this, our #diagnostics tests can safely and accurately rule out the presence of #bladder cancer in symptomatic patients. https://t.co/KPQoXdlcJq
Arquer Diagnostics @Arquer Diagnostics
Acting with #integrity is very important to us. We're committed to improving the lives of #cancer #patients and their families and work hard to ensure that all of our staff and shareholders adhere to this crucial #value. https://t.co/fj0N7y91j1
Arquer Diagnostics @Arquer Diagnostics
It's never been a more important time for #healthcare providers, with significant strain being placed on this hard-working industry. It's our aim to help in reducing overall healthcare #costs by creating products to improve the speed and success of #patient diagnosis. https://t.co/y0zkiyWO8t
Arquer Diagnostics @Arquer Diagnostics
#Endometrialcancer is the fourth most common #cancer found in women in the UK, with 9,300 women diagnosed every year. Abnormal vaginal bleeding is a common indication of this and those experiencing such symptoms should seek immediate medical advice. https://t.co/QtokwH1h22
